[Effect of a new cytostatic agent (peptichemio) on malignant neoplasms].
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D001984:Bronchial Neoplasms / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000188:drug therapy; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use*; D010649:Phenylalanine / Q000627:therapeutic use; D011086:Polycythemia / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D010455:Peptides; D010649:Phenylalanine
Zur Wirkung eines neuen Zytostatikums (Peptichemio) bei Malignomen.